Evaluation of the effects of and earliest response rate to anti-D treatment in children with chronic idiopathic thrombocytopenic purpura: A pilot study

Turkish Journal of Pediatrics

Volumn 52, Issue 2, 2010, Pages 126-131

  Yetgin, Sevgi ^a   Aytaç, Selin ^a   Olcay, Lale ^b   Tunç, Bahattin ^c   Özbek, Namik ^d   Aydinok, Yeim ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

^d BASKENT UNIVERSITY   (Turkey)

^e EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adverse effects; Anti D; Children; Chronic idiopathic thrombocytopenic purpura; Earliest response rate

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN; RHESUS D ANTIBODY; VINCRISTINE; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HEMOLYSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKOCYTE COUNT; MALE; PILOT STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RETICULOCYTE COUNT; SCHOOL CHILD; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ADOLESCENT; BLOOD GROUP RHESUS SYSTEM; IMMUNOLOGY; INFANT; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN; TREATMENT OUTCOME;

EID: 77955484385     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Yetgin S, Olcay L, Ozsoylu S, Hicsonmez G, Gurgey A, Tuncer AM. Retrospective analysis of 78 children with chronic idiopathic thrombocytopenic purpura: follow-up from 1976 to 1996. Pediatr Hematol Oncol 1997; 14: 399-412.
2. George JN, Woolf SH, Raskop GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
3. Blanchette VS, Chir B, Carcao M. Childhood acute immune thrombocytopenic purpura 20 years later. Semin Thromb Hemost 2003; 29: 605-617.
4. Ozsoylu S, Sayli TR, Ozturk G. Oral mega dose methylprednisolone versus intravenous immunoglobulin for acute childhood thrombocytopenic purpura. Pediatr Hematol Oncol 1993; 10: 317-320.
5. Ozsoylu S, Irken G, Karabent A. High-dose methylprednisolone for acute thrombocytopenic purpura. Eur J Hematol 1989; 42: 431-435.
6. Ozsoylu S. High dose intravenous methylprednisolone for treatment of childhood chronic thrombocytopenic purpura. Pediatr Rev Commun 1987; 2: 29-40.
7. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991; 77: 18841893.
8. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89: 2689-2700.
9. Freiberg A, Mauger D. Efficacy, safety and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. Semin Hematol 1998; 35: 23-27.
10. Tarantino MD, Madden RM, Fennewald DL, Patel CC, Bertolone SJ. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr 1999; 134: 21-26.
11. El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol 2006; 115: 46-52.
12. Simpson KN, Coughlin CM, Eron J, Bussel JB. Idiopathic thrombocytopenia purpura: treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy. Semin Hematol 1998; 35: 58-64.
13. Tarantino MD, Young G, Bertolone SJ, et al. A single dose of anti-D immune globulin at 75 μg/kg is as effective as IVIG at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura (ITP) in children. For the acute ITP study group. J Pediatr 2006; 148: 489-494.
14. Moser AM, Shalev H, Kapelushnik J. Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2002; 19: 407-411.
15. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of IV-anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112: 1076-1078.
16. Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M. Safety profile Win Rho anti-D. Semin Hematol 1998; 35 (Suppl): 9-13.
17. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o) (D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000; 95: 2523-2529.
18. Kees-Folts D, Abt AB, Domen RE, Freiberg AS. Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. Pediatr Nephrol 2002; 17: 91-96.
19. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106: 1532-1537.
20. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997; 350: 620-623.
21. Cooper N, Heddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms. Modulation of cytokine and platelet responses to IV anti-D by FcyRIIa and FcyRIIIa polymorphisms. Br J Haematol 2004; 124: 511-518.
22. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000; 37: 261-266.
23. Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol 1998; 35: 14-22.
24. Schwartz J, Spitalnik S, Grima KM. Severe hemolysis following administration of Rho(D) immune globulin in an ITP patient associated with anti-C. Blood 2006; 107: 2585.